Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, PDT, JVN

Canadian Hospital Specialties to Distribute Eitan Group's Sapphire Infusion Systems in Canada


NETANYA, Israel, Sept. 16, 2019 /CNW/ -- Eitan Group, a global leader in advanced infusion therapy solutions across the care continuum, today announced a distribution agreement with Canadian Hospital Specialties Ltd. (CHS), a national specialty distributor and manufacturer of medical and surgical products, to supply and support Eitan Group's Sapphire infusion system hospital and alternate site customers across Canada. 

"CHS works to introduce the most advanced medical technology to the Canadian market in our mission to improve patient care and outcomes," said Mike Canzoneri, CEO of CHS. "We are aligned with Eitan Group in our innovation focus; we believe our customers will immediately see the benefits of implementing Eitan Group's future-ready, intuitive Sapphire platform."

Sapphire customers will receive immediate attention and support across Canada with CHS's large, capable sales organization.   

"CHS has significant experience in hospital-based and alternate site infusion and has a reputation for providing high quality products with excellent customer service. CHS is an ideal partner to bring Sapphire to the Canadian market," said Roger Massengale, CEO of Eitan Group North America.

Eitan Group's flagship Sapphire infusion systems are installed worldwide, with more than 100,000 devices in the market. The robust infusion platform is lightweight with a small footprint, features an intuitive touch screen and is designed for ease-of-use, requiring minimal training for medical professionals.

About Eitan Group
Eitan Group is focused on infusion therapy and technologies, developing future-ready systems for hospital care and ambulatory settings, as well as wearable solutions for easy self-administration. Eitan Group initially entered the infusion market in 2009, and a decade later, with data on over 18 million liters of infusions completed, now consists of three affiliate companies: Q Core Medical, Sorrel Medical and Avoset Health. With a focus on innovating patient-centered care and safety, Eitan Group is reimagining infusion therapy with connected, software-based solutions.

Follow The Eitan Group on LinkedIn and Twitter

About Canadian Hospital Specialties Ltd.

CHS is a national speciality distributor and manufacturer of medical and surgical products, servicing the Canadian healthcare industry for more than 50 years. CHS is committed to offering impeccable service and introducing new and innovative products to the Canadian market. Our goal is to help improve patients' health outcomes and quality of life, coast to coast.

CHS Contact:
Jay Barat
Director, Business Development and Medication Delivery
[email protected]
647-270-3779

Eitan Group Contact:
[email protected]
877-541-9944 

Media Relations Contact:
Nicole Grubner
Finn Partners
+1 929-222-8011
[email protected] 

 

SOURCE Eitan Group


These press releases may also interest you

at 06:00
Biohaven Ltd. , a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its...

at 06:00
According to a Léger survey conducted for Transplant Québec, more than three in four people favour the adoption, by Québec, of specific and comprehensive legislation governing organ donation and transplantation. At a time when the National Assembly...

at 05:30
Children's Minnesota is thrilled to announce the 32nd annual Star Gala raised $2.3 million to benefit the nonprofit pediatric health system's neuroscience program. Star Gala is regarded as one of the biggest nights of the year for the Twin Cities...

at 04:04
The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomical...

at 03:30
Proprietary E3 ligase platform to enable protein stabilisation "at source", thereby restoring the body's sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges...

at 03:00
Todd Britten, DMD, a board-certified periodontist and dental implant specialist in...



News published on and distributed by: